Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:GHRS NASDAQ:HROW NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.08-0.3%$20.77$16.92▼$48.45$1.60B-0.0410,620 shs17,756 shsGHRSGH Research$23.61+6.9%$21.15$11.32▼$25.94$1.52B1.31271,016 shs301,518 shsHROWHarrow$42.78+0.9%$36.80$28.54▼$54.85$1.58B0.28753,773 shs1.30 million shsZURAZura Bio$4.30+1.7%$4.53$1.00▼$7.44$401.35M0.03953,578 shs1.25 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-0.29%+0.41%-18.71%-23.84%-54.02%GHRSGH Research+6.88%+18.17%+6.74%+72.97%+102.14%HROWHarrow+0.87%+11.41%+29.64%+17.69%+38.00%ZURAZura Bio+1.65%+22.16%-1.38%-23.49%+283.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.08-0.3%$20.77$16.92▼$48.45$1.60B-0.0410,620 shs17,756 shsGHRSGH Research$23.61+6.9%$21.15$11.32▼$25.94$1.52B1.31271,016 shs301,518 shsHROWHarrow$42.78+0.9%$36.80$28.54▼$54.85$1.58B0.28753,773 shs1.30 million shsZURAZura Bio$4.30+1.7%$4.53$1.00▼$7.44$401.35M0.03953,578 shs1.25 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-0.29%+0.41%-18.71%-23.84%-54.02%GHRSGH Research+6.88%+18.17%+6.74%+72.97%+102.14%HROWHarrow+0.87%+11.41%+29.64%+17.69%+38.00%ZURAZura Bio+1.65%+22.16%-1.38%-23.49%+283.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.20Buy$46.43171.83% UpsideGHRSGH Research 2.73Moderate Buy$40.3871.01% UpsideHROWHarrow 2.64Moderate Buy$69.4362.29% UpsideZURAZura Bio 2.67Moderate Buy$10.75150.00% UpsideCurrent Analyst Ratings BreakdownLatest ZURA, GHRS, AAPG, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026AAPGAscentage Pharma Group International BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.006/10/2026AAPGAscentage Pharma Group International Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026AAPGAscentage Pharma Group International B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/19/2026GHRSGH Research HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/15/2026GHRSGH Research CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/15/2026GHRSGH Research Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $35.005/15/2026GHRSGH Research Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$42.00 ➝ $39.005/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/12/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.004/24/2026AAPGAscentage Pharma Group International Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/22/2026HROWHarrow Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$574.12M2.78N/AN/A$2.04 per share8.37GHRSGH ResearchN/AN/AN/AN/A$4.51 per shareN/AHROWHarrow$272.30M5.86$0.87 per share49.07$1.41 per share30.34ZURAZura BioN/AN/AN/AN/A$1.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/AGHRSGH Research-$48.26M-$0.92N/AN/AN/AN/A-19.36%-18.73%8/6/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A19.81N/A-5.57%19.59%2.26%8/10/2026 (Estimated)ZURAZura Bio-$99.35M-$1.09N/AN/AN/AN/A-55.74%-48.07%8/13/2026 (Estimated)Latest ZURA, GHRS, AAPG, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026GHRSGH Research-$0.27-$0.31-$0.04-$0.31N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/7/2026Q1 2026ZURAZura Bio-$0.17-$0.22-$0.05-$0.22N/AN/A3/25/2026H2 2025AAPGAscentage Pharma Group InternationalN/A-$0.5150N/A-$0.5150N/A$24.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77GHRSGH ResearchN/A34.1334.13HROWHarrow10.302.482.30ZURAZura BioN/A19.3319.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AGHRSGH Research56.90%HROWHarrow72.76%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AGHRSGH ResearchN/AHROWHarrow12.80%ZURAZura Bio12.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.39 millionN/AN/AGHRSGH Research1068.61 millionN/AOptionableHROWHarrow18037.28 million32.50 millionOptionableZURAZura Bio394.88 million83.14 millionOptionableZURA, GHRS, AAPG, and HROW HeadlinesRecent News About These CompaniesZura Bio (NASDAQ:ZURA) and MiNK Therapeutics (NASDAQ:INKT) Head-To-Head AnalysisJune 17, 2026 | americanbankingnews.comZura Bio (ZURA) Gets a Buy from OppenheimerJune 13, 2026 | theglobeandmail.comHere's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn SituationJune 3, 2026 | finance.yahoo.comZura Bio Announces Board Resignation, Governance Stability AffirmedMay 22, 2026 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)May 11, 2026 | theglobeandmail.comZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | businesswire.comZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | businesswire.comZura Bio Limited Class AApril 24, 2026 | edition.cnn.comOne Zura Bio Insider Raised Their Stake In The Previous YearApril 23, 2026 | finance.yahoo.comPiper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA)April 16, 2026 | theglobeandmail.comZura Bio: Momentum Is Real, But TibuSHIELD Needs To DeliverMarch 31, 2026 | seekingalpha.comZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 19, 2026 | businesswire.comZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressMarch 5, 2026 | businesswire.comInsider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Acquires 2,000,000 Shares of StockMarch 3, 2026 | insidertrades.comZura Bio to Participate in Upcoming Investor ConferencesMarch 2, 2026 | businesswire.comZura Bio Raises $144 Million To Advance Autoimmune Drug PipelineFebruary 27, 2026 | ventureburn.comVZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesFebruary 27, 2026 | businesswire.comZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 25, 2026 | businesswire.comZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 24, 2026 | finance.yahoo.comZura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.February 23, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZURA, GHRS, AAPG, and HROW Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$17.08 -0.05 (-0.29%) Closing price 06/23/2026 03:49 PM EasternExtended Trading$17.14 +0.06 (+0.35%) As of 06/23/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.GH Research NASDAQ:GHRS$23.61 +1.52 (+6.88%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$23.14 -0.47 (-1.99%) As of 06/23/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Harrow NASDAQ:HROW$42.78 +0.37 (+0.87%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$42.84 +0.06 (+0.15%) As of 06/23/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Zura Bio NASDAQ:ZURA$4.30 +0.07 (+1.65%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$4.26 -0.04 (-0.81%) As of 06/23/2026 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
